More Articles Back to Article
Adaptimmune's synovial sarcoma drug gains PRIME status
The European Medicines Agency granted PRIME status to Adaptimmune's treatment for synovial sarcoma, ADP-A2M4. The tag will Adaptimmune access to additional support and guidance from the EMA to facilitate the drug's development. PharmaTimes online (UK) (7/28)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!